再生醫學市場規模、佔有率和成長分析：按產品、治療領域和地區分類 - 產業預測，2024-2031

Regenerative Medicine Market Size, Share, Growth Analysis, By Product (Cell Therapy, Gene Therapy), By Therapeutic Area (Oncology, Musculoskeletal Disorders), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月08日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球再生醫學市場規模將達到95.9億美元，從2023年的122億美元成長到2031年的836億美元，複合年成長率預計將成長27.2%。

再生醫學的主要目標是恢復因各種原因而喪失的功能。這包括修復和更換因老齡化、疾病或受傷而受損的組織和器官，以及解決出生缺陷。與傳統治療不同，再生醫學具有恢復更快等優點。幹細胞療法和富含血小板的血漿等技術可增強人體的自然癒合能力，加速受損組織的修復，減少發炎和疤痕組織的形成。包括內源幹細胞刺激和用於輕微組織損傷的類器官移植在內的新興技術預計將在未來幾年推動市場成長。幹細胞生物學的最新進展正在對再生醫學產生重大影響。我們提供從成體細胞創建多功能細胞以及在受控條件下從這些幹細胞培養微生物等創新，為創建用於修復和移植的功能性人體組織提供了新策略。政府的支持也是市場拓展的重要因素。歐盟（EU）和荷蘭政府強調再生醫學是一個重要的政策相關領域。在北美，由於社會老化，市場正在蓬勃發展。美國北卡羅來納州組織工程與再生醫學會正在積極推動該領域的研究與發展，NIH、CIRM等機構資助學術和轉化研究。全球醫療保健支出的成長預計也將提振市場。然而，資訊有限、使用胚胎幹細胞的倫理問題、高投資成本以及測試靈敏度和再現性問題等挑戰可能會阻礙市場成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 義大利
- 英國
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Novartis AG（Switzerland）
Biogen（US）
Sarepta Therapeutics, Inc.（US）
Gilead Sciences, Inc.（US）
Amgen, Inc.（US）
Smith & Nephew plc.（UK）
MEDIPOST Co., Ltd.（South Korea）
JCR Pharmaceuticals Co., Ltd（Japan）
Takeda Pharmaceutical Company（Japan）
CORESTEM Inc.（South Korea）
Orthocell Ltd.（Australia）
Mesoblast Ltd（Australia）
BioRestorative Therapies, Inc.（US）
Tegoscience（South Korea）
APAC Biotech（India）
Shenzhen SiBiono Genetech Co., Ltd.（China）
Aspect Biosystems（Canada）
Athersys, Inc.（US）
Terumo Corporation（Japan）
Vericel Corporation（US）

簡介目錄

Product Code: SQMIG35I2129

Global Regenerative Medicine Market size was valued at USD 9.59 Billion in 2022 and is poised to grow from USD 12.2 Billion in 2023 to USD 83.6 Billion by 2031, growing at a CAGR of 27.2% in the forecast period (2024-2031).

The primary aim of regenerative medicine is to restore function lost due to various causes. It involves repairing or replacing tissues and organs damaged by aging, disease, or injury, and addressing congenital abnormalities. Unlike traditional treatments, regenerative medicine offers advantages such as accelerated recovery. Techniques like stem cell therapy and platelet-rich plasma enhance the body's natural healing process, speed up the repair of damaged tissues, and reduce inflammation and scar tissue formation. Emerging methods, including endogenous stem cell stimulation and organoid transplantation for minor tissue injuries, are expected to drive market growth in the coming years. Recent advancements in stem cell biology have significantly impacted regenerative medicine. Innovations such as generating pluripotent stem cells from adult cells and cultivating microorganisms from these stem cells under controlled conditions have provided new strategies for creating functional human tissue for repair and transplantation. Government support is also a crucial factor in market expansion. The European Union and the Dutch government have emphasized regenerative medicine as a key area of policy relevance. In North America, the market is thriving due to the growing aging population. The North Carolina Tissue Engineering and Regenerative Medicine Society in the U.S. is actively promoting research and development in this field, while agencies like NIH and CIRM fund academic and translational research. Increasing global healthcare spending is also expected to boost the market. However, challenges such as limited information, ethical concerns over embryonic stem cell use, high investment costs, and issues with test sensitivity and reproducibility may hinder market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Regenerative Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Regenerative Medicine Market Segmental Analysis

Global regenerative medicine market is segmented based on Product, Therapeutic Category, Distribution Channel and Region. Based on Product, the market is segmented into Cell Therapy (Stem Cell Therapy {Cell Transplantations, Stem Cell Therapy Products [Autologous Therapy, Allogeneic Therapy]}, Cell-based Immunotherapy), Gene Therapy, And Tissue Engineering. Based on Therapeutic Area, the market is segmented into Oncology, Musculoskeletal Disorders, Dermatology & Wound Care, Cardiovascular Diseases, Ophthalmology, Neurology, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Regenerative Medicine Market

The increasing investment in the regenerative medicine market has spurred extensive research and development efforts, with investors backing start-ups dedicated to creating innovative treatments and products. This financial support has fostered research collaborations and mergers within the industry. Additionally, government investment plays a significant role, facilitating the development of effective treatment options for various chronic diseases, including cancer, diabetes, and kidney disease, among others.

Restraints in the Global Regenerative Medicine Market

The high cost of therapies and the absence of standardized reimbursement policies are major challenges hindering market growth. For instance, many stem cell therapies are classified as experimental or investigational, leading to limited coverage under Medicare. This often results in substantial out-of-pocket expenses for patients, as Medicare only covers FDA-approved treatments like allogeneic transplants. The lack of comprehensive insurance coverage forces patients to either pay for treatments out of pocket or seek crowdfunding, which can delay access to necessary care and stifle market expansion. Additionally, the scarcity of approved drugs for a broad range of genetic disorders, coupled with their high costs, further limits market growth and accessibility.

Market Trends of the Global Regenerative Medicine Market

A key trend in the global regenerative medicine market is the strategic acquisition of companies by major players to enhance their research and development capabilities. The market encompasses innovative products derived from living cells, proteins, enzymes, antibodies, antibody-drug conjugates (ADCs), and genetic materials, which are crucial for developing lifesaving treatments for various chronic diseases. However, translating these advanced technologies into clinical practice often reveals a gap between theoretical potential and real-world application. To address this, leading companies are increasingly turning to acquisitions to bolster their R&D efforts and advance the development of diverse clinical applications.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Start-up Analysis
PESTEL Analysis
Customer & Buying Criteria Analysis
Supply Chain Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Regenerative Medicine Market by Product

Market Overview
Cell Therapy
- Stem Cell Therapy
  - Cell transplantations
  - Stem cell therapy products
    - Autologous therapy
    - Allogeneic therapy
- Cell-based Immunotherapy
Gene Therapy
Cosmetics Implants
Tissue Engineering

Regenerative Medicine Market by Therapeutic Area

Market Overview
Oncology
Musculoskeletal Disorders
Dermatology & Wound Care
Cardiovascular Diseases
Ophthalmology
Neurology
Others

Regenerative Medicine Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- Italy
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sarepta Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith & Nephew plc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MEDIPOST Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JCR Pharmaceuticals Co., Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CORESTEM Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orthocell Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Ltd (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioRestorative Therapies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tegoscience (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
APAC Biotech (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shenzhen SiBiono Genetech Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspect Biosystems (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments